BioLife Solutions Deploys SciSafe's Ultra Low Controlled Temperature Trailers to Extend Domestic Cold Chain Services

Rhea-AI Summary

BioLife Solutions (NASDAQ: BLFS) has announced the launch of its SciSafe biostorage services platform, featuring ultra-low temperature (ULT) truck trailers for local cold chain movements of biologic materials. This service aims to enhance operational flexibility and reduce risks in transporting high-value assets for life sciences companies. The fleet can handle temperatures as low as -196°C, supporting efficient transportation without dry ice. Guidance for 2022 revenue ranges from $21.5 million to $26 million for storage services, contributing to a total revenue expectation of $159.5 million to $171 million.

Positive

• Introduction of ultra-low temperature trailers increases service offerings and enhances operational flexibility for clients.
• Ability to transport biologics without dry ice, improving efficiency and reliability.
• Projected revenue for 2022 encompasses significant growth, with storage services revenue estimated between $21.5 million to $26 million.

Negative

• None.

The new service will enable life sciences companies to seamlessly move hardware as well as biomaterials at the local level

BOTHELL, Wash., June 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced that its SciSafe^® biostorage services platform will now offer a fleet of refrigerated and ultra-low temperature ("ULT") truck trailers to manage local cold chain movements for customers' biologic materials.  This fleet provides an ideal transportation solution for any biologic product movement requiring ULT storage between -20°C and -196°C without the added need for dry ice as it moves from pharmaceutical manufacturer to contract development and manufacturing company ("CDMO") sites and can be deployed worldwide.  Running on generator power with two cooling systems, the fleet can also carry up to ten plugged in, powered, and running upright ULT freezers at a time, expanding supported temperatures to as low as -86°C with equipment to track location and trailer temperatures, in real time. The controlled temperature trailers can also transport liquid nitrogen storage freezers containing biologic materials stored at -150°C and colder.

From day-to-day sample management to deploying clinical trial medicines that need ULT freezers to clinical sites, life sciences organizations, and particularly large pharmaceutical companies, face significant challenges when moving high value assets that have stringent storage temperature requirements. This new domestic transport service enables operational flexibility and reduced risk through the same provider SciSafe customers already trust with their sample management. Furthermore, the ability to ship older freezers to SciSafe for management and replace them in-facility with newer models supports campus sustainability and helps to lower energy costs.

"Our ability to move client biomaterials safely at ultra-low temperatures is highly valued by pharmaceutical and cell and gene therapy companies," said Mike Rice, Chairman and CEO of BioLife Solutions. "This service also highly complements our internal use of our portfolio of cold chain products, including the evo^® DV10 Smart Shipper™, Stirling Ultracold^® freezers, and cryogenic liquid nitrogen storage freezers. These controlled temperature trailers expand the volume as well as the type of materials that can be moved and, in turn, increase the value we can offer our customers."

SciSafe recently moved 16 ULT freezers for long-term storage management for a top ten pharmaceutical company. The units arrived safely at the desired temperature and will now permanently live in the SciSafe biorepository.

Management guidance for 2022 storage and storage services revenue ranges from $21.5mm to $26mm, with total revenue in a range from $159.5mm to $171mm.

To learn more about this offering, please visit biologicalstorage.com. 

About BioLife Solutions

BioLife Solutions is a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets. Our tools portfolio includes our proprietary CryoStor^® and HypoThermosol^® biopreservation media for shipping and storage, the ThawSTAR^® family of automated, water-free thawing products, evo^® cold chain management system,  high capacity cryogenic storage freezers, Stirling Ultracold mechanical freezers, SciSafe biologic storage services, and Sexton Biotechnologies cell processing tools.  For more information, please visit www.biolifesolutions.com, www.scisafe.com, www.stirlingultracold.com, or www.sextonbio.com and follow BioLife on Twitter.

Cautions Regarding Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements about our ability to implement our business strategy and anticipated business and operations, including as it relates to the deployment of SciSafe's ultra-low temperature trailers to expand the volume as well as the type of materials that can be moved and, in turn, build upon the value of our existing offerings for our customers, and BioLife's plans, objectives, expectations, beliefs and intentions and other statements including words such as "hope," "anticipate," "may," "believe," "expect," "intend," "will," "should," "plan," "estimate," "predict," "continue" and "potential" or the negative of these terms or other comparable terminology. The forward-looking statements herein represent the judgment of BioLife, as of the date of this release, and BioLife disclaims any intent or obligation to update forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those currently anticipated. This press release should be read in conjunction with the information included in BioLife's other press releases, reports, and other filings with the SEC and on the SEC website, www.sec.gov. Understanding the information contained in these filings is important in order to fully understand BioLife's reported financial results and BioLife's business outlook for future periods. Actual results may differ materially from the results anticipated in the forward-looking statements and the assumptions and estimates used as a basis for the forward-looking statements.

Contact Information:

At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com

Investors
LHA Investor Relations
Jody Cain
(310) 691-7100
jcain@lhai.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-deploys-scisafes-ultra-low-controlled-temperature-trailers-to-extend-domestic-cold-chain-services-301564683.html

SOURCE BioLife Solutions, Inc.

FAQ

What new service has BioLife Solutions introduced for cold chain management?

BioLife Solutions has introduced ultra-low temperature (ULT) truck trailers as part of its SciSafe biostorage services platform to enhance local cold chain movements for biologic materials.

What temperatures can the new transportation solution from BioLife Solutions handle?

The new ultra-low temperature trailers can transport materials at temperatures ranging from -20°C to -196°C.

What are the expected revenue figures for BioLife Solutions in 2022?

BioLife Solutions anticipates storage services revenue between $21.5 million and $26 million, contributing to total revenue expected between $159.5 million and $171 million.

How does the new service from BioLife Solutions benefit life sciences companies?

The service provides operational flexibility and reduces risks associated with transporting high-value biologic materials, enhancing reliability in cold chain logistics.